VIRACTA THERAPEUTICS INC (VIRX) Stock Analyst Ratings
USA - NASDAQ:VIRX - US92765F1084 - Common Stock
0.0778 USD
-0.07 (-48.65%)
0.071 USD
-0.01 (-8.74%)
ChartMill assigns a Buy % Consensus number of 43% to VIRX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 3.06. This target is 3833.16% above the current price.
VIRX was analyzed by 6 analysts. The buy percentage consensus is at 43. So analysts seem to be rather negative about VIRX.
In the previous month the buy percentage consensus was at a similar level.
VIRX was analyzed by 6 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-12-27 | Rodman & Renshaw | Downgrade | Buy -> Neutral |
| 2024-11-14 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-08-16 | Leerink Partners | Downgrade | Outperform -> Market Perform |
| 2024-08-15 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-05-23 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-04-17 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2024-04-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-12 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-01-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-11-10 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023-10-05 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-08-15 | SVB Securities | Maintains | Outperform -> Outperform |
| 2023-08-15 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-07-31 | EF Hutton | Initiate | Buy |
| 2023-07-05 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-10 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-05-09 | RBC Capital | Maintains | Outperform |
| 2023-03-27 | Oppenheimer | Maintains | Outperform |
| 2023-03-14 | RBC Capital | Reiterate | Outperform |
| 2023-03-14 | HC Wainwright & Co. | Reiterate | Buy |
| 2022-11-11 | RBC Capital | Maintains | Outperform |
| 2021-05-03 | HC Wainwright & Co. | Initiate | Buy |
| 2021-04-26 | SVB Leerink | Initiate | Outperform |
| 2021-03-25 | Evercore ISI Group | Initiate | Outperform |
VIRACTA THERAPEUTICS INC / VIRX FAQ
What is the price target for VIRX stock?
6 analysts have analysed VIRX and the average price target is 3.06 USD. This implies a price increase of 3833.16% is expected in the next year compared to the current price of 0.0778.
What is the consensus rating for VIRACTA THERAPEUTICS INC (VIRX) stock?
The consensus rating for VIRACTA THERAPEUTICS INC (VIRX) is 43.3333 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
What is the number of analysts for VIRX stock?
The number of analysts covering VIRACTA THERAPEUTICS INC (VIRX) is 6.